Vanguard Global Advisers
RANI icon

Vanguard Global Advisers’s Rani Therapeutics RANI Stock Holding History

Vanguard Global Advisers’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.1K Hold
31,751
– – ﹤0.01% 3273
2026
Q1 		$23.3K Buy
+31,751
New +$40.6K ﹤0.01% 3261

Other funds holding RANI

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LP
Longaeva Partners Chicago, Illinois $4.58B AUM 43.91% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Vanguard Global Advisers's RANI Position: Q2 2026 in Review

Vanguard Global Advisers held its Rani Therapeutics (RANI) position steady in Q2 2026 at 31,751 shares worth $24.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3273.

Vanguard Global Advisers first reported a position in RANI in Q1 2026 and has held it in 2 quarters since. 65 funds tracked by Wall St. Rank hold RANI as of Q2 2026.

  • Vanguard Global Advisers held 31,751 shares of Rani Therapeutics worth $24.1K as of Q2 2026.
  • Vanguard Global Advisers left its Rani Therapeutics share count unchanged in Q2 2026.
  • Rani Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3273 holding.
  • Vanguard Global Advisers first reported a position in Rani Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 65 funds tracked by Wall St. Rank held Rani Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.